Supernus Raises 2024 Total Revenue Guidance From $580M-$620M To $600M-$625M vs $600.12M Est.
Portfolio Pulse from Benzinga Newsdesk
Supernus Pharmaceuticals has raised its 2024 total revenue guidance from $580M-$620M to $600M-$625M, compared to the $600.12M estimate.
August 06, 2024 | 8:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Supernus Pharmaceuticals has increased its 2024 revenue guidance to $600M-$625M, which is above the previous range and the $600.12M estimate.
The increase in revenue guidance indicates a positive outlook for Supernus Pharmaceuticals, suggesting better-than-expected performance. This is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100